SLC25A46: A Potential Drug Target for Diabetes (G91137)

Target Name: SLC25A46

NCBI ID: G91137

SLC25A46

SLC25A46: A Potential Drug Target for Diabetes

SLC25A46 (S2546_HUMAN) is a protein that is expressed in various tissues of the human body. It is a member of the SLC family, which is known for its involvement in the transport of various molecules across cell membranes. One of the unique aspects of SLC25A46 is its expression pattern, which is highly selective for the liver and pancreas.

The SLC25A46 protein is approximately 46 kilodalton (kDa) in size and has a calculated pI of approximately 6.5. It is expressed in a variety of tissues, including the liver, pancreas, and muscle. In the liver, SLC25A46 is predominantly expressed in the periportal zone, which is the region surrounding the portal vein that brings blood into the liver. In the pancreas, it is expressed in the islet尾-cells, which are responsible for producing insulin. In muscle, it is expressed in the myofibers.

SLC25A46 is involved in the transport of various molecules across cell membranes, including glucose, insulin, and other proteins. It is a critical regulator of glucose homeostasis, as it is responsible for maintaining the stability of glucose levels in the body. It is also involved in the regulation of insulin secretion from the pancreas, as it is known to interact with the insulin secretion machinery.

SLC25A46 is a potential drug target in the treatment of various diseases, including diabetes. Diabetes is a chronic metabolic disorder that is characterized by high levels of blood glucose and a lack of insulin. It is a leading cause of morbidity and mortality, and is a major public health issue.

SLC25A46 has been shown to be involved in the regulation of insulin secretion from the pancreas. It has been shown to interact with the insulin secretion machinery and to play a role in the regulation of insulin sensitivity. This suggests that SLC25A46 may be a useful target for the treatment of diabetes.

SLC25A46 has also been shown to be involved in the regulation of glucose homeostasis. It is involved in the transport of glucose across cell membranes and is a critical regulator of glucose levels in the body. This suggests that SLC25A46 may be a useful target for the treatment of hypoglycemia, which is a common complication in diabetes.

SLC25A46 has also been shown to be involved in the regulation of other physiological processes in the body. It is involved in the regulation of ion channels, which are responsible for the flow of electrical current through cells. It is also involved in the regulation of signaling pathways, which are responsible for the communication of signals between cells.

In conclusion, SLC25A46 is a protein that is expressed in various tissues of the human body and is involved in the transport of various molecules across cell membranes. It is a potential drug target in the treatment of diabetes and hypoglycemia, as well as other physiological processes in the body. Further research is needed to fully understand the role of SLC25A46 in the regulation of insulin secretion, glucose homeostasis, and other physiological processes in the body.

Protein Name: Solute Carrier Family 25 Member 46

Functions: Transmembrane protein of the mitochondrial outer membrane that controls mitochondrial organization (PubMed:26168012, PubMed:27543974, PubMed:27390132). May regulate the assembly of the MICOS (mitochondrial contact site and cristae organizing system) complex which is essential to the biogenesis and dynamics of mitochondrial cristae, the inwards folds of the inner mitochondrial membrane (PubMed:27390132). Through its interaction with the EMC (endoplasmic reticulum membrane protein complex), could regulate mitochondrial lipid homeostasis and thereby mitochondrial fission (PubMed:27390132)

The "SLC25A46 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A46 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets